Andrew Schiermeier is VP at Intellia Therapeutics, Inc. (NTLA). They have made 2 open-market trades across 1 company since 2019, most recently 2021-01-05.
CIK 0001738456
1 open-market purchase totalling $118K since 2019, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NTLA | 18,033 | $206K |
Shares reported on the most recent Form 4, priced at the 2021-01-05 close.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.